Antibody Neutralization Mechanisms

$1,808,122ZIAFY2022AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Paper 38873606 Paper 38802413 Paper 38773089 Paper 38704686 Paper 38587079 Paper 38430907 Paper 38232141 Paper 38177144 Paper 37436900 Paper 37436899 Paper 37345226 Paper 37295404 Paper 37104089 Paper 37098956 Paper 37075126 Paper 36976017 Paper 36931276 Paper 36848985 Paper 36729903 Paper 36382536 Paper 35841885 Paper 35736810 Paper 35709309 Paper 35589938 Paper 35568025 Paper 35489332 Paper 35438546 Paper 35413243 Paper 35324257 Paper 34836485 Paper 34726473 Paper 34408080 Paper 34328065 Paper 34244481 Paper 34242577 Paper 34210892 Paper 34200826 Paper 34111408 Paper 34098567 Paper 34019795 Paper 33876699 Paper 33827946 Paper 33823129 Paper 33794145 Paper 33790470 Paper 33789084 Paper 33649208 Paper 33214287 Paper 32877670 Paper 32698192 Paper 32596696 Paper 32561362 Paper 32561270 Paper 32268107 Paper 32196859 Paper 32130953 Paper 31488690 Paper 31473167 Paper 31216462 Paper 30760721 Paper 30297708 Paper 29975771 Paper 29578688 Paper 29558468 Paper 29554083 Paper 29548671 Paper 29514901 Paper 29444432 Paper 28931639 Paper 28878010 Paper 28783708 Paper 28747530 Paper 28539926 Paper 28514685 Paper 28133812 Paper 28076415 Paper 28052137 Paper 27908641 Paper 27851912 Paper 27820605 Paper 27708645 Paper 27610571 Paper 27581986 Paper 27477385 Paper 27453470 Paper 27299673 Paper 27191167 Paper 27174988 Paper 27064278 Paper 27053554 Paper 26949186 Paper 26485194 Paper 26468542 Paper 26468324 Paper 26446600 Paper 26413851 Paper 26085162 Paper 26041300 Paper 26023780 Paper 26004070

Abstract

Highly effective neutralizing antibodies could have utility in the prevention or treatment of infection from HIV-1, malaria, and other human pathogens, including the recently emerged SARS-CoV-2. Much of our work with neutralizing antibodies has focused on identifying, characterizing and in many case improving naturally elicited antibodies. Improved HIV-1 neutralizing antibodies include versions of CD4-binding site-directed antibodies capable of neutralizing over 95% of HIV, and some of these have been manufactured and assessed clinically. We are also working in collaboration with other groups to identify and to characterize effective neutralizing antibodies against other human pathogens. Overall, our antibody-related work involves understanding and improving antibodies, as possible therapeutic agents against HIV-1, SARS-CoV-2, malaria and other human pathogens.

View original record on NIH RePORTER →